Search company, investor...

Predict your next investment

Venture Capital
mpmcapital.com

Investments

436

Funds

16

Partners & Customers

4

Service Providers

3

About MPM Capital

MPM Capital is a Boston-based life science-dedicated venture investor with committed capital under management in excess of $2 billion. MPM invests in biotechnology, specialty pharma, medical technology, and related companies that provide innovative medical products and requisite services to the healthcare industry, irrespective of geography, stage of development and therapeutic area.

Headquarters Location

450 Kendall Street

Cambridge, Massachusetts, 02142,

United States

617-425-9200

Want to inform investors similar to MPM Capital about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Research containing MPM Capital

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned MPM Capital in 1 CB Insights research brief, most recently on Oct 17, 2022.

Latest MPM Capital News

NextPoint Therapeutics Reports $80 Million Series B for Novel Immuno-Oncology Programs

Jan 19, 2023

NextPoint Therapeutics has announced an $80 million Series B funding round to move two lead precision immuno-oncology programs into the clinic. Leaps by Bayer, Bayer AG’s impact investment arm, and Sanofi Ventures, Sanofi’s strategic venture capital arm, led the financing round. Both programs of the Boston-based company use the recently discovered HHLA2 (HERV-H LTR-associating 2) pathway to turn on immune responses that fight tumors. Detlev Biniszkiewicz, PhD, CEO of NextPoint Therapeutics, Managing Director at MPM, and Entrepreneur at BioImpact Capital, an affiliate manager of MPM. “We discovered another checkpoint axis that is independently expressed from PD-1/L1 that nobody currently works on,” Detlev Biniszkiewicz, PhD, CEO of NextPoint, told GEN Edge. “The hope is to develop something very similar to the successful PD-1 therapies. We have really strong IP around this axis, so part of the proceeds will be used to develop the research on this axis further. While we have an opportunity to develop our pipeline further, most of the proceeds will be used to bring two lead projects into the clinic.” Some of the other new investors in this round are Sixty Degree Capital, Catalio Capital Management, Invus, and PagodaTree Partners. Along with NextPoint’s co-founder, Gordon Freeman, PhD, best known for discovering the PD-L1 and PD-L2 proteins, existing investors MPM Capital Management, Binney Street Capital, Dana-Farber Cancer Institute, and others participated in the financing. As a result of the financing, Paulina Hill, who is a Partner at Sanofi Ventures, and Rakhshita Dhar, who is the Senior Director of Venture Investments Health at Leaps by Bayer, will join the NextPoint Board of Directors. A tale of two checkpoints NextPoint is the brainchild of two scientific founders who independently discovered the HHLA2 pathway: alongside Freeman, of the Dana-Farber Cancer Institute, is Xingxing Zang, PhD, of Albert Einstein College of Medicine. “In 2018, Gordon Freeman approached [MPM Capital Management] with this new and really exciting news,” said Biniszkiewicz. “After doing some research, we discovered that Xingxing Zang also independently discovered this novel pathway. We combined the work of both researchers into one company, which was really exciting because they are both leaders in the field.” In both the gut and the lung, PD-1 is often found where tissue meets the lumen. “If you think about where the bacteria from the gut lumen interact with the lung, this is often where those molecules suppress immune activity,” said Biniszkiewicz. “The gut sees so much bacteria that if it were constantly inflamed, it wouldn’t function. Tumors learn to hijack this pathway to protect themselves, and we know that tumors upregulate PD-1 to protect themselves from the immune system.” Most human tissues don’t have HHLA2, a ligand for receptor CD28H (TMIGD2 or IGPR1), but, according to Biniszkiewicz, immune cells in the placenta and intestines do. This is to help fetal-maternal immune tolerance or control inflammation in the intestines. Many human cancers overexpress HHLA, including cancers of the breast, lung, melanoma, pancreas, ovary, liver, colon, prostate, and esophagus. “We discovered that HHLA2 is upregulated in an independent set of patients to protect against the immune system,” Biniszkiewicz said. “Similar to PD-1, we can select HHLA2-positive patients who are often PD-1-negative and drive monotherapy in these patients. So, the excitement is that [HHLA2] is another checkpoint, the closest we have seen to the PD-1/L1 pathway.” MPM Capital Management invested slightly more than $2 million to seed NextPoint in 2020 and has been growing it since. “We have about 15-20 employees and intend to grow it further as we go into clinical development, making sure we have the right resources to push those projects into the clinic,” said Biniszkiewicz, who is a Managing Director at MPM and Entrepreneur at BioImpact Capital, an affiliate manager of MPM. He is also a board member of MPM’s portfolio company, iTeos Therapeutics (NASDAQ: ITOS). “Almost 95% of current immuno-oncologists are focused on making PD-1 therapy better—we are not one of those companies,” said Biniszkiewicz. “I cannot tell you how unique it is to really work on patients that do not benefit from PD-1 therapy. I think that is really the key unmet medical need.” Share

MPM Capital Investments

436 Investments

MPM Capital has made 436 investments. Their latest investment was in NextPoint as part of their Series B on December 12, 2022.

CBI Logo

MPM Capital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

12/19/2022

Series B

NextPoint

$80M

No

9

12/2/2022

Seed VC

Arialys

$14.33M

Yes

Avalon Ventures, MPM Capital, and Undisclosed Investors

1

9/8/2022

Series A

Photys

$75M

Yes

7

8/25/2022

Series A - II

Subscribe to see more

$99M

Subscribe to see more

10

12/2/2021

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

12/19/2022

12/2/2022

9/8/2022

8/25/2022

12/2/2021

Round

Series B

Seed VC

Series A

Series A - II

Series B

Company

NextPoint

Arialys

Photys

Subscribe to see more

Subscribe to see more

Amount

$80M

$14.33M

$75M

$99M

$99M

New?

No

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Avalon Ventures, MPM Capital, and Undisclosed Investors

Sources

9

1

7

10

10

MPM Capital Acquisitions

3 Acquisitions

MPM Capital acquired 3 companies. Their latest acquisition was Pacira Biosciences on March 05, 2007.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

3/5/2007

Debt

$99M

$111.25M

Acq - Fin

8/15/2001

Other Venture Capital

Subscribe to see more

$99M

$99M

Subscribe to see more

0

6/12/2001

Subscribe to see more

$99M

Subscribe to see more

10

Date

3/5/2007

8/15/2001

6/12/2001

Investment Stage

Debt

Other Venture Capital

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

Total Funding

$111.25M

$99M

Note

Acq - Fin

Subscribe to see more

Subscribe to see more

Sources

0

10

MPM Capital Fund History

16 Fund Histories

MPM Capital has 16 funds, including MPM Oncology Impact Fund II.

Closing Date

Fund

Fund Type

Status

Amount

Sources

10/6/2021

MPM Oncology Impact Fund II

$850M

1

2/26/2020

MPM Oncology Innovations Fund

Early-Stage Venture Capital

Closed

$98.88M

5

2/21/2019

MPM BioVentures 2018

Early-Stage Venture Capital

Closed

$400M

5

7/9/2015

MPM BioVentures 2014

Subscribe to see more

Subscribe to see more

$99M

10

3/24/2015

MPM Bio 2014 NVS Strategic Fund

$99M

10

Closing Date

10/6/2021

2/26/2020

2/21/2019

7/9/2015

3/24/2015

Fund

MPM Oncology Impact Fund II

MPM Oncology Innovations Fund

MPM BioVentures 2018

MPM BioVentures 2014

MPM Bio 2014 NVS Strategic Fund

Fund Type

Early-Stage Venture Capital

Early-Stage Venture Capital

Subscribe to see more

Status

Closed

Closed

Subscribe to see more

Amount

$850M

$98.88M

$400M

$99M

$99M

Sources

1

5

5

10

10

MPM Capital Partners & Customers

4 Partners and customers

MPM Capital has 4 strategic partners and customers. MPM Capital recently partnered with DigiTx Partners, and Astellas Pharma on April 4, 2019.

Date

Type

Business Partner

Country

News Snippet

Sources

4/22/2019

Partner

United States, and Japan

Astellas Launches DigiTx Partners, a Digital Health Investment Company in Partnership with MPM Capital — digiTx Partners

Tokyo and San Francisco , July 29 , 2016 -- Astellas Pharma Inc. and DigiTx Partner 's LLC announce that Astellas Pharma Inc. has launched DigiTx Partners LLC , a digital health investment company in partnership with MPM Capital , Inc. .

1

7/30/2016

Partner

Japan

Subscribe to see more

Subscribe to see more

10

5/14/2015

Partner

Switzerland

Subscribe to see more

Subscribe to see more

10

Partner

Japan

Subscribe to see more

Subscribe to see more

10

Date

4/22/2019

7/30/2016

5/14/2015

Type

Partner

Partner

Partner

Partner

Business Partner

Country

United States, and Japan

Japan

Switzerland

Japan

News Snippet

Astellas Launches DigiTx Partners, a Digital Health Investment Company in Partnership with MPM Capital — digiTx Partners

Tokyo and San Francisco , July 29 , 2016 -- Astellas Pharma Inc. and DigiTx Partner 's LLC announce that Astellas Pharma Inc. has launched DigiTx Partners LLC , a digital health investment company in partnership with MPM Capital , Inc. .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

10

10

10

MPM Capital Service Providers

3 Service Providers

MPM Capital has 3 service provider relationships

Service Provider

Associated Rounds

Provider Type

Service Type

Counsel

General Counsel

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Service Provider

Subscribe to see more

Subscribe to see more

Associated Rounds

Provider Type

Counsel

Subscribe to see more

Subscribe to see more

Service Type

General Counsel

Partnership data by VentureSource

MPM Capital Team

52 Team Members

MPM Capital has 52 team members, including current Founder, Managing Director, Luke Evnin.

Name

Work History

Title

Status

Luke Evnin

Founder, Managing Director

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Luke Evnin

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

Title

Founder, Managing Director

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.